You have successfully logged out.
Press Releases
Here you will find all our recent press releases, media information, financial news as well as photos and contacts.
Thursday, 17 August 2023
The Supervisory Board of B. Braun SE has appointed Mrs. Ingrun Alsleben as member of the Executive Board of B. Braun SE effective January 1, 2024. Mrs. Alsleben comes from the Bayer Group, where she was most recently responsible for the countries Turkey/Iran as CEO and CFO. As of April 1, 2024, Ingrun Alsleben is to take over the position of Chief Financial Officer from Dr. Annette Beller, who will retire.
Read moreThe Aesculap Academy education portfolio and global centres have been awarded global accreditation by the Royal College of Surgeons of England (RCS England) for three years until March 2026.
Read more
Friday, March 23, 2023
The B. Braun Group recorded 8.5 billion euros in sales in FY 2022 (previous year: 7.9 billion euros). Adjusted for currency effects, this is an increase of 3.6 percent. The result was burdened by high expenses to maintain supply availability as well as one-off effects.
Read moreSchölly Fiberoptic GmbH is once again undergoing a reorganization of its shareholding structure. Aesculap AG will become the sole shareholder on January 1, 2023 and will thus take over the entire company shares of the family business.
Read more
Protecting and improving the health of people around the world is the
vision that has driven the medical technology company B. Braun,
based in Melsungen, Germany, for 183 years.
Prof. Dr. Dr. h.c. Michael Ungethüm passed away on August 4 at the age of 78. He was Chairman of the Management Board of Aesculap AG for 19 years and a member and Vice Chairman of the Management Board of what is now B. Braun SE from 2000 to 2009.
Read more
B. Braun's surgical division Aesculap has a new Management Board. After Dr. Jens von Lackum had already taken over as Chairman of the Management Board effective April 1st, 2022, the Aesculap Supervisory Board yesterday appointed two new members to the Management Board: Prof. Dr. Holger Reinecke and Andreas Hahn will join the board on July 1st, 2022.
Read moreWith the conclusion of a new distribution agreement, B. Braun surgery division Aesculap has strengthened its long-term partnership with True Digital Surgery, a Californian company that is an expert in robotically controlled 3D digital visualization.
Read more
B. Braun has decided to sell its provider and hospital services business in Colombia. Effective March 16, the local company Grupo Uros will take over all dialysis centers including their approx. 230 clinical employees. B. Braun has provided high-quality dialysis care to up to 2,000 patients over the last eight years.
Read moreThe B. Braun Group increased its sales in FY 2021 by 5.8 percent year over year, to €7,859.9 million (previous year: €7,426.3 million). Thanks to extraordinary efforts, B. Braun was able to ensure delivery capability to its customers, even with significant added pressure on the supply chains.
Read more
Effective April 1, 2022, Dr Meinrad Lugan will change from the B. Braun SE Executive Board to the Executive Board of affiliated company B. Braun Familienholding Verwaltungs SE at his own request as part of a planned generational change. Dr. Lugan is thus giving up his responsibilities for the Hospital Care division.
Read moreWith the full integration of Intermedt Medizin & Technik GmbH into the Group, B. Braun has completed the extensive product portfolio of its B. Braun Avitum division as a systems provider for extracorporeal blood treatment (dialysis).
Read more
B. Braun celebrated the official ground-breaking of a state-of-the-art Haemodialysis Concentrate Factory in the Thanh Oai Industrial Complex in Hanoi, Vietnam on January 10, 2022.
Read moreAt its meeting on December 7th 2021, the Supervisory Board of B. Braun SE appointed Dr Jens von Lackum as deputy member of the Management Board of B. Braun SE.
Read more
B. Braun and REVA Medical hereby announce the strategic partnership for the distribution of Fantom® Encore - a bioresorbable scaffold for coronary interventions, manufactured with REVA's patented material Tyrocore.
Read more
Christine Bossak
Vice President Group Internal & External Communications
